An2 Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is An2 Therapeutics Inc's ROI in the second quarter of 2026?
An2 Therapeutics Inc recorded a cumulative net loss of $-36 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -53.38%.

Within the Healthcare sector 488 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3091 to 3756.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-15.85 %	-26.71 %	-37.23 %	-33.07 %	-34.53 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	76	82	53	61	70
Return On Investment (TTM)	-53.38 %	-52.1 %	-54.74 %	-45.94 %	-46.29 %
ANTX's Overall Ranking	# 3756	# 3091	# 3311	# 3419	# 3000
Seq. Investment Change TTM	2.46 %	3.2 %	-13.13 %	-8.39 %	-10.75 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-36	-35	-35	-34	-37

ANTX Company Profile >> Back to ANTX Roi Comparisons >> See Annual ANTX Return On Investment

Return On Investment ANTX's Ranking
Within:	No.
Industry	# 207
Sector	# 489
Overall	# 3756

Return On Investment Statistics
High	Average	Low
-26.53 %	-50.39 %	-59.67 %
(Mar 31 2022)		(Dec 31 2023)

News about An2 Therapeutics Inc Return on Investment ROI

AN2 Therapeutics Implements Stockholder Rights Plan Amid Significant Share Accumulation Implications for Stakeholders

August 16, 2024

AN2 Therapeutics, a biopharmaceutical firm dedicated to developing innovative small molecule therapeutics through its proprietary boron chemistry platform, has adopted a limited duration stockholder rights plan in response to a notable increase in ownership stakes by an investment partner. This article examines the motivations behind this strategic decision, its potential implications for the company, and the broader context of corporate governance in the biopharmaceutical industry. In an evolving marketplace characterized by rapid shifts in stakeholder dynamics, AN2 Therapeutics, Inc. (Nasdaq: ANTX) has taken a proactive approach to fortify its corporate governance structure. This decision comes on the heels of a significant stock accumulation 19.3% by BML Investment Partners, prompting the company to adopt a limited duration stockholder rights plan set to expire on August 15, 2025. Such measures are increasingly common among biopharmaceutical companies aiming to safeguard their interests while navigating the complexities of equity ownership and control.

Financial Statements
An2 Therapeutics Inc's II. Quarter Investments	$ 76 Millions	ANTX's Balance sheet
An2 Therapeutics Inc's II. Quarter Income	$ -8 Millions	Quarterly ANTX's Income Statement
ANTX's Income by Division		See ANTX's Income by Division

ANTX Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022
Total Investments in Millions	53	92	125	95	0
Y / Y Investment Growth	-42.2 %	-26.15 %	30.75 %	-	-
Net Income in Millions	-35	-51	-65	-41	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-66.08 %	-55.73 %	-51.91 %	-42.94 %	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ANTX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ANTX's Competitors
Subscribers only: Roi for An2 Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for ANTX's Customers

Other Ratios
ANTX's Roa	ANTX's Inventory Turnover Ratio	ANTX's Growth Rates	ANTX's Dividend Statistics
	ANTX's Profitability Ratios	ANTX's Asset Turnover Ratio	ANTX's Dividend Growth
ANTX's Roe	ANTX's Valuation Ratios	ANTX's Financial Strength Ratios	ANTX's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:41:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.